Development and optimization of therapeutic anti-CXCR3 monoclonal antibodies

We have recently discovered a very potent antibody targeting the chemokine receptor CXCR3, a promising target for the treatment of inflammatory and autoimmune diseases. The role of the student will be to use the capabilities within the host laboratory and the Monash Antibody technology Facility (MATF) to: (1) Generate high affinity antibodies against CXCR3 using our affinity maturation platform (2) Characterise the most promising affinity matured antibodies using a wide variety of cell based assays and immunological techniques such as Surface Plasmon Resonance, Immunohistochemistry or flow-cytometry. The host laboratory has had extensive success in this approach with many therapeutic antibodies, which are part of collaborative work with industry partners. This is an excellent opportunity for a driven student to experience high-end technology to make significant new discoveries in the field of drug development.